PFD Capital Partners

One of the things we've come to appreciate over time is that most important decisions don't arrive with complete information. Whether it's an investment, a business opportunity, or a major life decision, there is almost always some level of uncertainty involved.

The people who consistently make good decisions aren't necessarily better at predicting the future. More often, they have a process. They ask questions, look for evidence, and take the time to understand what sits beneath the surface before moving forward.

That's one of the biggest lessons from The Frog Files: better decisions are rarely the result of luck. More often, they're the result of discipline, preparation, and thoughtful evaluation.

Find out more at https://pfdfamilyofcompanies.com/the-frog-files-lessons-in-better-decisions-stronger-businesses-and-smarter-investing/

Another milestone for the PFD Family of Companies.

PFD recently announced the closing of PFDSelect Medical Receivables 1018, LLC (PFDSMR1018), the 17th SPE in our 1000 Series.

What makes this milestone particularly meaningful is the participation behind it: 99 investors joined the offering, including 75 investors who were new to PFD and 24 existing investors who chose to participate again. We were also pleased to welcome 34 new investors through referrals.

As our platform continues to grow, we remain focused on the same priorities that have guided us from the beginning: supporting medical service providers, maintaining disciplined operations, and building long-term relationships based on communication, transparency, and trust.

We are grateful to our investors, providers, partners, and team members who continue to be part of this journey.

Learn more about PFDSMR1018 and the continued growth of PFD at

Blog - PFD Family Of Companies Our Blog Articles & Thought Leadership

A proud development we've been following recently comes from Regeneration Biomedical, Inc. (RBI), a company focused on advancing regenerative medicine approaches for Alzheimer's disease.

Earlier this month, RBI presented Phase I clinical findings at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting in Dublin, one of the leading global conferences dedicated to cell and gene therapy research.

As a healthcare-focused investment platform, PFD is always interested in innovations that seek to address significant unmet medical needs. While clinical development is a long process and much work remains ahead, it's encouraging to see continued progress in areas where patients and families are still waiting for better solutions.

We recently shared our perspective on why developments like this matter and how they fit within our broader view of healthcare innovation.

Read the full article on our website: https://pfdfamilyofcompanies.com/blog/

At PFD Capital Partners, we believe strong investment platforms are built on more than performance alone.

They are built on structure, discipline, transparency, and alignment across every participant involved.

PFD operates within the healthcare and personal injury ecosystem, helping create financial stability in an area where timing, coordination, and consistency matter deeply. Our platform is designed to support:
• Patients receiving access to care
• Providers operating with reduced financial uncertainty
• Attorneys focused on advocacy
• Compliance frameworks that protect system integrity
• Investors seeking disciplined, risk-conscious opportunities

What makes PFD different is not just what we do, but how we do it.

Our company is built around:
✔ Operational discipline
✔ Repeatable systems
✔ Compliance-first ex*****on
✔ Transparent investor communication
✔ Long-term relationship building

Find out more at https://pfdfamilyofcompanies.com/blog/

Happy Tuesday! Some of our IRA investors have recently received a notice about K-1s and potential UBIT (Unrelated Business Taxable Income).
This is a standard custodian communication—not specific to PFD—and we want to provide some clarity.
Here’s what matters:
• These notices are routinely sent when an IRA investment issues a K-1
• UBIT generally applies to active business income or leveraged income
• PFD investors are passive limited partners (no control or management rights)
• Based on counsel and CPA guidance, UBIT is not expected to apply
• IRA-related K-1s should not be included on your personal tax return
As always, you can share your K-1 with your tax advisor for confirmation.
If you have questions, we’re here to help.

PFD Family getting together for Evan & Robert’s Birthday! 🔥 Happy Friday!

ITS A 7-11 BIRTHDAY 🔥💚 Happy Birthday to Evan Leonard & Robert Pryke! Thank you for all you add to our team. Happy Friday!

🔥 Progress doesn’t wait for perfect timing.
It moves when you do.

Midweek momentum starts with intention.

FDA momentum unlocked. 🔓
One of PFD Capital’s medical technology partners, Cassderma Rx, has received FDA preliminary clearance to advance its lead therapy, CAS101, toward Phase 2 clinical trials, pending final studies.

CAS101 is a patented topical treatment designed to help restart the body’s natural healing process for patients suffering from chronic, non-healing wounds. This rare regulatory step accelerates development and brings the program closer to patients who urgently need better options.

We’re proud to support innovation like this and to stand behind partners working to move healthcare forward.

Find more information at pfdfamilyofcompanies.com/press-releases/

Ringing in the New Year with the PFD Family 🥂✨ Great people, great memories, and plenty to celebrate as we start 2026 together! Here’s to another year of teamwork, growth, and good times!